MK 886

Drug Profile

MK 886

Alternative Names: L 663536; MK 0886

Latest Information Update: 18 Feb 2008

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiallergics; Antiasthmatics; Antineoplastics; Antipsoriatics
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors; DNA synthesis inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Cancer; Coronary thrombosis; Inflammatory bowel diseases; Psoriasis; Thrombosis; Transplant rejection

Most Recent Events

  • 08 Sep 1998 No-Development-Reported for Thrombosis in USA (unspecified route)
  • 08 Sep 1998 No-Development-Reported for Coronary thrombosis in USA (unspecified route)
  • 29 Mar 1996 An animal study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top